Novo Nordisk stock after-hours at EUR 33.14: minus 0.48 percent versus prior close
Published on 10/02/2026 at 18:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novo Nordisk stock was at EUR 33.14 after-hours at 6:50 p.m. CEST on October 2, 2026, down 0.48 percent versus the EUR 33.30 prior close at Lang & Schwarz.
Friday’s trading
The latest Lang & Schwarz price was EUR 33.14, compared with a EUR 33.30 prior close. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Novo Nordisk stock.
HRS-1596 licensing agreement
On September 29, 2026, Hengrui Pharma announced that Novo Nordisk had entered into an exclusive license agreement for HRS-1596, a phase I-ready GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing. Novo obtained rights to develop, manufacture and commercialize the treatment globally except in mainland China, Hong Kong, Macao and Taiwan. The potential deal value is up to USD 2.6 billion, including a USD 300 million upfront payment, with additional milestone payments and royalties. The transaction is expected to close in the fourth quarter of 2026 and remains subject to customary conditions, according to PR Newswire.
EASD data presentations
In a September 16, 2026 release, Novo Nordisk said it would present 44 abstracts at the European Association for the Study of Diabetes annual meeting in Milan from September 28 through October 2. The company highlighted data covering semaglutide, CagriSema, zenagamtide and the Wegovy pill across obesity, diabetes, cardiovascular, kidney and liver-related outcomes, according to Novo Nordisk.
